32 results on '"Labenz, J"'
Search Results
2. Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two-way crossover study including CYP2C19 genotyping
3. A false sense of security; symptom control does not predict healing of oesophagitis on proton pump inhibitors: Authorʼs reply
4. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis - results from the maintenance phase of the EXPO study
5. Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care - a 5-year follow-up
6. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study
7. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study
8. Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: a matched case–control study
9. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care – results from the ProGERD study
10. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrettʼs mucosa
11. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus
12. Lifestyle factors and symptoms of gastro-oesophageal reflux – a population-based study
13. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study1
14. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study
15. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study
16. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease — an analysis based on the ProGERD initiative
17. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study
18. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole
19. High rate of post-therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study
20. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease
21. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients
22. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
23. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer
24. One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection
25. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care - the ProGERD study
26. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping
27. Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease
28. Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
29. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pyloriinfection in duodenal ulcer patients
30. Efficacy and tolerability of a one‐week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pyloriinfection in patients with duodenal ulcer
31. One‐week low‐dose triple therapy for Helicobacter pyloriis sufficient for relief from symptoms and healing of duodenal ulcers
32. Balanced perspective essential in erosive oesophagitis treatment: Author's reply.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.